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Abstract
Background: The vascular endothelial growth factor (VEGF)-VEGF receptor (VEGFR) signaling pathway is involved
in cancer-related biological functions and is a therapeutic target in cancer. However, the influence of epigenetic
regulation of VEGF-VEGFR signaling-related genes remains unclear. Here, we evaluated the effects of FLT1 and
KDR promoter hypermethylation combined with drugs targeting VEGF-VEGFR signaling on cancer-related
phenotypes in renal cancer cells (RCCs) and examined changes in FLT1 and KDR promoter hypermethylation in
tissues from patients with renal cancer.
Results: In vitro experiments were performed to evaluate the effects of beavacizumab (an anti-VEGF antibody),
an anti-FLT1 peptide, an anti-KDR antibody, and the VEGFR tyrosine kinase inhibitors (TKIs) sunitinib and axitinib
in 13 RCC lines with different levels of FLT1 and/or KDR promoter methylation and in 2 FLT1 or KDR in vitro
knockdown models. The synergistic effects of sunitinib and axitinib treatment were also evaluated in four RCC
lines having different levels of FLT1 and/or KDR methylation. In our in vitro experiments, bevacizumab and an
anti-KDR antibody did not affect the proliferation of RCCs having FLT1 and/or KDR hypermethylation. In contrast,
in RCCs with FLT1 hypermethylation, proliferation inhibition was counteracted by treatment with an anti-FLT1
peptide and both VEGF-TKIs (sunitinib and axitinib). Demethylation with sunitinib or axitinib synergistically increased
proliferation inhibition in the RCCs exhibiting FLT1 hypermethylation. Using in vitro FLT1 or KDR knockdown models,
decreased proliferation inhibition following anti-FLT1 peptide, sunitinib, and axitinib treatment was observed only in
FLT1-knockdown cells. In patients with renal cancer who received sunitinib, FLT1 promoter methylation was higher in
renal cancer tissues from eight nonresponders (stable or progressive disease assessed by the Response Evaluation
Criteria in Solid Tumors) than in cancer tissues from five responders (complete response or partial response).
Conclusions: The present data showed that hypermethylated FLT1 was important for the efficacy of anti-VEGF/VEGFR
drugs targeting FLT1 or intracellular VEGFR signaling. FLT1 hypermethylation causing alterations of FLT1 function could
serve as a useful biomarker for predicting changes in FLT1 status in RCCs.
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Background
Vascular endothelial growth factor (VEGF)-VEGF recep-
tor (VEGFR) signaling is a critical step for autocrine mito-
genesis and paracrine angiogenesis during tumor growth
[1]. A variety of drugs targeting VEGF-VEGFR signaling
(anti-VEGF/VEGFR drugs) have been successful in halting
or regressing tumor growth in various in vitro and in vivo
studies [2]. However, these anti-VEGF/VEGFR drugs have
only modest effects in patients with cancer [2]. Although
studies have evaluated the anti-angiogenic mechanisms of
anti-VEGF/VEGFR drugs in order to understand the lack
of success in the clinical setting [3], additional studies are
needed to further elucidate other mechanisms supporting
these observations.
For anti-VEGF/VEGFR drugs to be effective in cancer
cells, active VEGF-VEGFR signaling should occur in can-
cer cells, as occurs in endothelial cells. In a previous
study, endothelial cells showed no epigenetic gene silen-
cing of VEGF, VEGFR1 (FLT1), or VEGFR2 (KDR), and
cell proliferation could be inhibited by treatment with an
anti-VEGF antibody, an anti-KDR antibody, or VEGF
tyrosine kinase inhibitors (TKIs) [4]. However, in some
cancer cells, changes in intracellular VEGF-VEGFR sig-
naling occur due to epigenetic gene silencing of FLT1
and KDR [5]. Cell lines having epigenetic gene silencing
of both FLT1 and KDR show insufficient inhibition of
proliferation after treatment with VEGF-TKIs [4]. While
a previous study showed evidence that intact VEGF-
VEGFR signaling is necessary for the successful effects of
anti-VEGF/VEGFR drugs, [4] the study was conducted
using cancer cells that originated from various human tis-
sues, and the individual roles of FLT1 or KDR epigenetic
gene silencing were not appropriately evaluated. There-
fore, the potential success or failure of anti-VEGF/VEGFR
drugs in cancer cells originating from different tissue types
and with different levels of FLT1 or KDR methylation re-
mains unclear.
In the present study, we aimed to analyze whether epi-
genetic alterations in FLT1 and/or KDR are related to
the anti-cancer effects of drugs targeting VEGF-VEGFR
signaling in renal cancer cells (RCCs) and in tissues
collected from renal cancer patients.
Results
Methylation of the FLT1 and KDR promoters in RCC lines
First, we examined the levels of VEGF, FLT1, and KDR
promoter methylation in select cell lines by pyrose-
quencing to target a sequence in promoter region of
each gene (Fig. 1a, b). Human umbilical vein endothe-
lial cells (HUVECs) showed less than 4 % methylation
of VEGF, FLT1, and KDR (Table 1). In contrast, 13 RCC
lines that were tested showed less than 1 % promoter
methylation of VEGF but variable methylation (from 2 to
90 %) for FLT1 or KDR (Table 1) . The increase in pro-
moter methylation for FLT1 (r = 0.839, R2 = 0.701, p =
0.000) and KDR (r = 0.669, R2 = 0.448, p = 0.012) corre-
sponded to an increase in ΔCT values in real-time reverse
transcription polymerase chain reaction (RT-PCR) experi-
ments (Fig. 2a, b).
Methylation of the FLT1 and KDR promoters in renal
cancer tissues and in sequences deposited in The Cancer
Genome Atlas (TCGA) database
To evaluate whether epigenetic gene silencing occurs in
renal cancer tissue, we analyzed the relationship be-
tween promoter methylation and expression of VEGF,
FLT1, and KDR in normal vs. cancer tissues collected
from eight renal cancer patients (Fig. 3). Normal and
cancer tissues showed less than 2 % promoter methyla-
tion for VEGF (p = 0.641). However, FLT1 (normal,
1.3 %; cancer tissue, 4.4 %; p = 0.023) and KDR (2.2 %
vs. 16.4 %; p = 0.008) methylations were significantly
higher in cancer tissues, compared to normal tissues
(Fig. 3). Next, we tested for associations between ex-
pression and methylation of FLT1 and KDR in renal
cancer tissues. This was done by performing correlation
analysis between the reciprocal of the percent methyla-
tion of either promoter and the relative quantity (RQ)
of gene expression to determine statically significant
linear correlation coefficients. The corresponding re-
gression equations were as follows:
RQ of FLT1 ¼ 1:3302þ 1:7336  1
FLT1 methylation
ðp ¼ 0:0669Þ
RQ of KDR ¼ 7:9906þ 0:3335  1
KDR methylation
p ¼ 0:048ð Þ
Analysis of data in TCGA deposited under the category
“renal clear cell carcinoma” revealed that the expression of
VEGFA (Spearman correlation r = −0.563, p < 0.00001),
FLT1 (r = −0.302, p < 0.00001), and KDR (r = −0.213, p =
0.000123) inversely correlated with methylation of their
respective promoters, based on data from 320 clear cell
RCC samples in TCGA (Fig. 4).
The effects of anti-VEGF/VEGFR drugs varied according to
the promoter methylation status of FLT1 or KDR
The proliferation of HUVECs was effectively inhibited
after treatment with five different anti-VEGF/VEGFR
drugs targeting different aspects of the VEGF-VEGFR
signaling pathway (an anti-VEGF antibody, bevacizu-
mab, an anti-KDR-antibody, an anti-FLT1 peptide, and
2 VEGF-specific TKIs, sunitinib and axitinib) for 72 h
(Fig. 2c). H460 cells, a control cell line having low methy-
lation of the FLT1 and KDR promoters, showed no prolif-
eration inhibition with bevacizumab or treatment with an
anti-KDR antibody. However, increased proliferation
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inhibition was observed by treatment with the anti-FLT1
peptide, sunitinib, or axitinib (Fig. 2c). SNU1 cells, a con-
trol cell line exhibiting high methylation of the FLT1 and
KDR promoters, showed no proliferation inhibition fol-
lowing treatment with any of these agents (Fig. 2c).
The 13 RCC lines tested were classified into four
groups based on the methylation level of FLT1 and/or
KDR: low methylation of both genes (both low methyla-
tion; SNU482 and SNU228 cells), high methylation of
FLT1 and low methylation of KDR (high FLT1/low KDR
methylation; SN12C and SN12PM6 cells), low methyla-
tion of FLT1 and high methylation of KDR (low FLT1/
high KDR methylation; A704, ACHN, Caki-1, and
SNU1272 cells), and high methylation of both genes
(both high methylation; SNU333, SNU349, A498, and
SNU267 cells), as detailed in Table 1. The cutoff methy-
lation levels required for classification as low or high
methylation was 15 % of pyrosequencing results for
FLT1 or KDR. RCCs showed different proliferation
inhibition patterns according to the levels of FLT1 and
KDR methylation observed following treatment with
the 4 VEGF different pathway inhibitors (Fig. 2c). Cells
exhibiting no methylation of FLT1 and KDR or low
FLT1/high KDR methylation exhibited proliferation in-
hibition patterns similar to that of H460 cells, i.e., no
significant proliferation inhibition caused by treatment
with bevacizumab and the anti-KDR antibody, but pro-
liferation inhibition was caused by the anti-FLT1 pep-
tide and VEGF-TKIs (sunitinib and axitinib). In contrast,
cells exhibiting high methylation of both genes or high
FLT1/low KDR methylation had proliferation inhibition
patterns similar to that of SNU1 cells, i.e., no significant
proliferation inhibition by any of the tested anti-VEGF/
VEGFR drugs.
Generalized linear mixed model (GLMM) analysis was
performed to evaluate whether high methylation FLT1
or KDR was related to proliferation inhibition by any of
the five drugs in RCCs. This analysis showed that
Fig. 1 Promoter CpG islands (a) and VEGF, FLT1, and KDR pyrosequencing in 2 RCC lines (b). Closed bars, exon 1 region for each gene; arrows,
translation start site; open bars, the region targeted for pyrosequencing; black segments within open bars, locations of sequencing primers for
each gene
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proliferation inhibition of each drug tested was not signifi-
cantly different between RCC cells exhibiting low and
high KDR methylation (bevacizumab: t = 0.44, p =
0.6612; anti-KDR antibody: t = 0.67, p = 0.5096; anti-
FLT1 peptide: t = 0.00, p = 0.9987; sunitinib: t = 0.28, p
= 0.7790; axitinib: t = 0.84, p = 0.4077). However, in
RCCs with high FLT1 methylation, the proliferation-
inhibitory effects of the anti-FLT1 peptide (t = 5.28, p <
0.0001), sunitinib (t = 4.77, p < 0.0001), and axitinib (t =
3.78, p = 0.0005) were significantly decreased compared
to RCCs with low FLT1 methylation, while growth in-
hibition caused by bevacizumab (t = 0.55, p = 0.5869)
and the anti-KDR antibody (t = 1.16, p = 0.2519) was
similar between cells exhibiting low and high FLT1
methylation.
Different synergistic proliferation-inhibitory effects of
sunitinib and axitinib after demethylation, according to
the promoter methylation status of FLT1 and/or KDR
Four RCC lines (SNU482, having low methylation of
both FLT1 and KDR; SN12C, having high FLT1/low
KDR methylation; ACHN, having low FLT1/high KDR
methylation; and SNU333, having high methylation of
both FLT1 and KDR) were used for demethylation ex-
periments. All four cell lines showed no significant
changes in demethylation (0–2 %) or expression of
Fig. 2 Expression changes and anti-VEGF/VEGFR drug efficacies associated with FLT1 and KDR methylation changes. Analysis of gene expression
of FLT1 (a) and KDR (b) in 13 RCC lines. Evaluation of the effects of bevacizumab, an anti-FLT1 peptide, an anti-KDR antibody, sunitinib, and axitinib
on RCC line proliferation was classified according to the hypermethylation status of FLT1 and/or KDR (c). H460 cells and SNU1 cells were used as
control cell lines that lacked or high methylation of either gene, respectively . The error bars show standard errors
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VEGF (RQ, 0.3–0.8) after 5-aza-2′-deoxycytidine
(DAC) treatment (data not shown)). However, after
DAC treatment, SNU333 cells showed significant de-
methylation and increased FLT1 expression (methyla-
tion change, −9 %; RQ, 28.0) and KDR expression
(methylation change, −6 %; RQ, 2.9); ACHN cells
showed significant changes in methylation and expression
of KDR (methylation change, −11 %; RQ, 17.3), and
SN12C cells showed significant changes in methylation
and expression of FLT1 (methylation change, −19 %; RQ,
34.1; Fig. 5a, b). SNU482 cells showed marked increases
in KDR expression (RQ, 88.1); however, no significant
Fig. 3 VEGF, FLT1, and KDR promoter methylation and expression differences between normal and cancer tissues. Normal, normal tissues; cancer,
cancer tissues collected from eight renal cancer patients
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demethylation was observed for either FLT1 (methyla-
tion change, 1 %) or KDR (0.1 %; Fig. 5a, b).
The control cell line H460, which has low methyla-
tion of FLT1 and KDR, showed a marked inhibition of
proliferation following treatment with sunitinib or axi-
tinib alone. However, combination treatment with DAC
and either sunitinib or axitinib showed a lower syner-
gistic effect on proliferation inhibition in H460 cells
than in SNU1 cells (Fig. 5c). In contrast, SNU1 cells
having high FLT1 and KDR promoter methylation,
showed no proliferation inhibition following treatment
with sunitinib or axitinib. However, the combination
treatment of DAC with sunitinib or axitinib exerted
marked synergistic effects on proliferation inhibition. In
RCCs, the proliferation inhibition of both SNU482 (low
methylation of FLT1 and KDR) and ACHN (low FLT1/
high KDR methylation) cells was promoted by sunitinib
or axitinib treatment, which was enhanced to a lesser
degree by demethylation, similar to H460 cells. Con-
versely, the proliferation of SN12C (high FLT1/low
KDR methylation) and SNU333 (high methylation of
FLT1 and KDR) cells was synergistically inhibited by
combination treatment with DAC and either sunitinib
or axitinib, similar to SNU1 cells, although sunitinib or
Fig. 4 Expression differences associated with promoter methylation
changes of the VEGF, FLT1, and KDR genes in TCGA. The query process
was performed using the cBioPortal online tools (www.cbioportal.org)
Table 1 Groups of renal cancer cell lines by the promoter
methylation status of FLT1 and KDR
Tissue origin Cell line Methylation (%) Group
VEGF FLT1 KDR
EC HUVEC 2 1 4 Both low (EC control)
Stomach SNU1 0 93 83 Both high
(cancer cell control)
Lung H460 0 3 8 Both low
(cancer cell control)
Kidney SNU482 0 4 11 Both low
SNU228 0 2 11 Both low
SN12C 0 65 3 High Flt1/low KDR
SN12PM6 0 45 3 High Flt1/low KDR
A704 0 11 82 Low Flt1/high KDR
ACHN 0 2 70 Low Flt1/high KDR
Caki-1 0 5 49 Low Flt1/high KDR
SNU1272 0 4 39 Low Flt1/high KDR
Caki-2 0 8 25 Low Flt1/high KDR
SNU333 1 80 50 Both high
SNU349 0 89 80 Both high
A498 0 90 36 Both high
SNU267 1 20 37 Both high
EC endothelial cell, HUVEC human umbilical vein endothelial cell, both low low
methylation (<15 %) of both FLT1 and KDR, high Flt1/low KDR high
methylation (>15 %) of FLT1 and low methylation of KDR, low FLT1/high KDR
low methylation of FLT1 and high methylation of KDR, both high high
methylation of both FLT1 and KDR
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axitinib treatment alone did not significantly inhibit
proliferation (Fig. 5c).
Three-factor analysis was used to evaluate the relation-
ship between FLT1 or KDR hypermethylation with the
effects of combination treatment of demethylation
with VEGF-TKIs in RCCs. This analysis revealed that
RCCs exhibiting low FLT1 methylation were more sensi-
tive to sunitinib (t = 11.68, p < 0.0001) or axitinib (t =
10.96, p < 0.0001) treatment than cells exhibiting high
FLT1 methylation. After combination treatment with
DAC plus sunitinib (DAC + sunitinib: t = −3.40, p =
0.0011) or axitinib (DAC + axitinib: t = −5.87, p < 0.0001),
cells exhibiting high FLT1 methylation exhibited greater
proliferation inhibition than cells with low FLT1 methyla-
tion. In contrast, RCCs having low or high KDR methyla-
tion did not exhibit significant differences in proliferation
inhibition after combination treatment with DAC and su-
nitinib (t = 1.89, p = 0.0620), DAC and axitinib (t = −1.23,
p = 0.2240), or treatment with sunitinib (t = 0.99, p =
0.3242) or axitinib (t = −0.52, p = 0.6040) alone.
Effects of FLT1 or KDR knockdown on the sensitivity of
RCCs to anti-VEGF/VEGFR drugs
FLT1 expression (RQ) was significantly decreased to
0.027 (t = 131.53, p = 0.000) in FLT1-knockdown SNU
482 cells transduced with a lentiviral vector expressing a
short hairpin RNA (shRNA) against FLT1 (Fig. 6a). Simi-
larly, KDR expression (RQ) was significantly decreased
to 0.198 (t = 45.75, p = 0.000) in KDR knockdown cells
(Fig. 6b).
Analysis of proliferation revealed that the proliferation
inhibition of control SNU482 cells transduced with an
Fig. 5 FLT1 and KDR expression and the proliferation-inhibitory effects of sunitinib or axitinib after demethylation treatment. Promoter methylation
and gene expression were evaluated after demethylation treatment in RCC lines. Changes in expression (RQ) and methylation (%) in FLT1 (a) and
KDR (b) after demethylation using DAC, a demethylating agent. Proliferation of RCC lines following treatment with sunitinib or axitinib and/or
DAC(c). The error bars show standard errors
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empty lentiviral vector was increased after treatment
with the anti-FLT1 peptide, sunitinib, or axitinib (Fig. 6c).
Similar proliferation inhibition was observed following
treatment with the anti-FLT1 peptide, sunitinib, or
axitinib in KDR knockdown cells, as observed with the
control SNU482 cells. However, none of these drugs
affected proliferation in FLT1-knockdown cells (Fig. 6c).
Two-factor analysis was used to evaluate the rela-
tionship between FLT1 and KDR knockdown with the
proliferation-inhibitory effects of the five anti-VEGF/
Fig. 6 Expression changes and anti-VEGF/VEGFR drug efficacies following knockdown of FLT1 or KDR in vitro. Expression of FLT1 (a) and KDR (b) in
SNU482 renal cancer cells after transduction with an shRNA targeting FLT1 or KDR. The effects of bevacizumab, an anti-FLT1 peptide, an anti-KDR
antibody, sunitinib, and axitinib on proliferation were evaluated in SNU482 cells transduced with lentiviral vectors expressing FLT1 or KDR or an
empty lentiviral vector (c). The error bars show the standard errors
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VEGFR drugs. In FLT1-knockdown SNU482 cells, the
growth inhibition by the anti-FLT1 peptide (t = 6.04,
p < 0.0001), sunitinib (t = 6.87, p < 0.0001), and axitinib
(t = 5.09, p < 0.0001) were significantly decreased, while
that in cells treated with bevacizumab (t = −1.09, p =
0.2766) and anti-KDR antibody (t = −1.34, p = 0.1818) did
not change. In KDR knockdown SNU482 cells, none of
the drugs tested affected the cell proliferation (bevacizu-
mab: t = −1.81, p = 0.0735; anti-KDR-antibody: t = −0.99,
p = 0.3257; anti-FLT1 peptide: t = 0.28, p = 0.7794; suniti-
nib: t = −1.46, p = 0.1483; axitinib: t = −0.26, p = 0.7961).
Methylation statuses of VEGF, FLT1, and KDR in patients
with RCC treated with sunitinib
To evaluate whether the methylation statuses of VEGF,
FLT1, or KDR of renal cancer tissues are related to pa-
tient responses to sunitinib, we compared the methyla-
tion statuses of these targets in cancer tissues from 13
patients with RCC who were treated with sunitinib.
The baseline characteristics of these patients are listed
in Additional file 1: Table S1. Among these patients,
five were responders (complete response, n = 1; partial
response, n = 4), as assessed by the Response Evaluation
Criteria in Solid Tumors (RECIST) criteria [6] and
eight patients were nonresponders (stable disease, n = 5;
progressive disease, n = 3). The responses to treatment
were confirmed after 2 or 3 cycles of sunitinib, and the
duration responses ranged from 9.7 to 22.8 months
(Additional file 2: Table S2). The methylation statuses
of VEGF (2.34 ± 0.21 % and 2.64 ± 0.91 % for re-
sponders vs. nonresponders, respectively; p = 0.240) and
KDR (22.88 ± 13.59 % and 24.41 ± 13.05 % for re-
sponders vs. nonresponders, respectively; p = 0.422)
were not significantly different between responders and
nonresponders. However, FLT1 promoter methylation
was significantly higher in nonresponders (6.84 ± 1.19 %
and 19.48 ± 13.15 % for responders vs. nonresponders,
respectively; p = 0.030; Fig. 7).
Discussion
In this study, we examined the effects of FLT1, KDR,
and VEGF promoter methylations and expressions on
the efficacy of anti-VEGF/VEGFR drugs in RCCs. The
results provided pharmacoepigenomic evidence indicat-
ing that FLT1 is necessary to achieve effective inhibition
of cell proliferation by drugs targeting the VEGF-VEGFR
signaling axis in RCCs.
In this study, we found that anti-VEGF/VEGFR drugs
inhibited cancer cell proliferation through mechanisms
other than the inhibition of angiogenesis [2]. In previous
studies, anti-VEGF/VEGFR drugs targeting extracellular
VEGF (bevacizumab) [7], VEGFRs (the anti-FLT1 pep-
tide [8] or anti-KDR antibody [9]), or intracellular VEGFR
signaling (VEGF-specific TKIs) [10] were shown to have
anti-angiogenic effects. In the present study, however,
drugs targeting FLT1 (anti-FLT1 peptide) or intracellular
VEGFR signaling (sunitinib and axitinib) showed signifi-
cant proliferation inhibition in RCCs having no epigenetic
alteration of FLT1. These findings suggested that the ef-
ficacies of various anti-VEGF/VEGFR drugs may differ
based on the specific target within the VEGF-VEGFR
signaling pathway in RCCs. In particular, VEGF-FLT1
and intracellular VEGFR signaling are important targets
required for achieving successful inhibition by anti-
VEGF/VEGFR drugs in RCCs. Furthermore, decreased
proliferation inhibition was observed after FLT1 knock-
down in an RCC lacking methylation of both FLT1 and
KDR. These data indicated that the various anti-VEGF/
VEGFR drugs tested inhibit cell proliferation through
different targets within the VEGF-VEGFR signaling
pathway in cancer cells. In particular, a lack of epigen-
etic alterations of the FLT1 promoter may be the most
important factor to consider when predicting the effi-
cacy of anti-VEGF/VEGFR drugs in RCCs.
The epigenomic evidence provided in the present study
showed that epigenetic gene silencing of FLT1 caused by
promoter hypermethylation was associated with insuffi-
cient inhibition of RCC proliferation by anti-VEGF/
VEGFR drugs. Although epigenetic alterations have been
reported as a mechanism contributing to cancer develop-
ment [11], the therapeutic applications of epigenetic alter-
ations in cancer treatment are not yet known [12]. Results
from the present study showed that the epigenetic alter-
ation of FLT1, but not KDR, was related to insufficient
inhibition of proliferation by anti-VEGF/VEGFR drugs,
particularly drugs targeting FLT1 and intracellular VEGFR
signaling. Synergistic inhibition of RCC proliferation after
Fig. 7 VEGF, FLT1, and KDR methylation in responder and
nonresponder patients with renal cancer receiving sunitinib. An
analysis of VEGF, FLT1, and KDR methylation statuses is shown for
responders and nonresponders. NR nonresponder, R responder, *p< 0.05
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combination treatment with a demethylating agent and
sunitinib or axitinib (VEGF-TKIs) supported the import-
ance of epigenomic FLT1 modification in the efficacy of
anti-VEGF/VEGFR drugs.
The present pharmacoepigenomic evidence suggested
that FLT1 could be a useful biomarker for predicting the
efficacy of anti-VEGF/VEGFR drugs targeting FLT1 and
intracellular VEGFR signaling. In the clinical setting, the
anti-cancer effects of anti-VEGF/VEGFR drugs are unsat-
isfactory, despite promising results from several in vitro
and in vivo experimental studies [2]. Researchers have
suggested that these limited effects of anti-VEGF/VEGFR
drugs may be due to the heterogeneous nature of tumor
structures and the susceptibility of tumor blood vessels to
anti-angiogenic therapy in different types of cancer [2].
However, VEGF is usually overexpressed in a variety of
different types of cancer, including renal [13], breast [14],
and ovarian cancers [15]. Moreover, paracrine-angiogenic
and autocrine-mitogenic pathways function simultan-
eously to promote tumor growth [1]. While anti-VEGF/
VEGFR drugs are thought to function via anti-angiogenic
effects [3], antimitogenic effects may also be involved. The
relationship between FLT1 epigenetic alterations and anti-
VEGF/VEGFR drug efficacy suggested that the FLT1
methylation status could be used as a biomarker to pre-
dicting the success of these drugs and as an epigenetic
mechanism to understand the failure of these drugs in
some patients with renal cancer.
Additional studies are required to examine whether
the present pharmacoepigenomic evidence can facilitate
the development of appropriate clinical management
strategies for patients with renal cancer. First, an evalu-
ation of the lower limit of FLT1 hypermethylation is
needed to develop methods for predicting the efficacy of
anti-VEGF/VEGFR drugs, particularly those targeting
FLT1 or intracellular VEGFR signaling. In this study, we
used a criterion of over 15 % methylation to define high
methylation of both FLT1 and KDR in RCC lines. In
methylation analysis using tissues collected from the
RCC patients of the present study, FLT1 methylation
showed a mean of 4 % in cancer tissues, even though
that degree of methylation was significantly higher than
observed in normal tissues from RCC patients. In con-
trast, renal cancer tissues from nonresponders to suniti-
nib had average of 20 % methylation at the FLT1
promoter. Well-designed clinical and experimental
studies are needed to verify the level of FLT1 hyper-
methylation associated with lack of efficacy of anti-
VEGF/VEGFR drugs. Additional clinical studies are also
needed to evaluate the significance of FLT1 hypermethyla-
tion in patients with cancer who have received anti-
VEGF/VEGFR drugs as second-line drugs in combination
chemotherapy. Previous studies have reported the effi-
cacy of adding anti-VEGF/VEGFR drugs, such as
bevacizumab [16] or VEGF-specific TKIs (PTK/ZK)
[17], to other cancer drugs in the management of can-
cers. However, the additive effects of anti-VEGF/
VEGFR drugs were variable. The role of FLT1 hyperme-
thylation in the efficacy of anti-VEGF/VEGFR drugs as
supporting drugs has not been well characterized. Thus,
evaluation of the function of FLT1 hypermethylation in
combination therapies should also be performed. Fi-
nally, the relevance of FLT1 methylation for predicting
the efficacy of anti-VEGF/VEGFR agents in other types
of cancers should also be examined. FLT1 methylation
has been observed in lung, stomach, and colon cancer
cells [4, 5]. In addition, the effects of VEGF-specific
TKIs have been shown to vary according to the methy-
lation status of VEGFR in other cancer types [4].
Conclusions
The present study provided pharmacoepigenomic evi-
dence to support the importance of FLT1 in predicting
the anti-cancer effects of anti-VEGF/VEGFR drugs. In-
tact VEGF-VEGFR signaling has been hypothesized to
enable successful growth inhibition in cancer tissues [5].
Thus, our results may explain the importance of intact
VEGF-VEGFR signaling in the efficacy of anti-VEGF/
VEGFR drugs. In particular, VEGF-FLT1 signaling may
be an important target for anti-VEGF/VEGFR therapy in
patients with cancer. Therefore, the promoter methyla-
tion status of FLT1 could be a useful biomarker to
anticipate successful effects of anti-VEGF/VEGFR drugs
targeting FLT1 or the intracellular tyrosine kinase activity
of VEGFR.
Methods
Cancer cell lines and tissues
The SNU1 cell line was used as a control cell line and
showed hypermethylation of both the FLT1 and KDR pro-
moters. H460 cells were used as another control cell line,
which lacked methylation of both genes, and HUVECs
were used as a control cell line to test the effects of anti-
VEGF/VEGFR drugs on proliferation. Six RCC lines
(A498, A704, ACHN, CAKI1, CAKI2, and SN12C) were
maintained in Dulbecco’s Modified Eagle’s Medium
(Gibco, Grand Island, NY, USA), while six other RCC lines
(SNU1272, SNU228, SNU333, SNU349, SNU482, and
SNU267) and the control cell lines (SNU1 and H460)
were maintained in Roswell Park Memorial Institute
(RPMI) 1640 medium (Gibco). The RCC line SN12PM6
was maintained in Modified Eagle Medium (Gibco). All
media used for maintaining cancer cell lines contained
10 % fetal bovine serum (FBS, Gibco). HUVECs were
grown in EGM-2 MV Endothelial Growth Medium
(EGM-2 MV Bulletkit; Lonza Walkersville, Walkers-
ville, MD, USA) for cell proliferation inhibition assays
or otherwise maintained in EGM-2 Basal Medium
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(Lonza Walkersville) containing less than 2 % FBS. All
RCC lines and SNU1 cells were purchased from the
Korean Cell Line Bank (Seoul, South Korea), whereas
H460 and HUVECs were purchased from the American
Type Culture Collection (Manassas, VA, USA).
To evaluate epigenetic gene silencing in renal cancer
tissues, we used normal and cancer tissues collected
from eight renal cancer patients, which were provided
by the Keimyung Human Bio-Resource Bank. The nor-
mal and cancer tissue samples were simultaneously col-
lected within 30 min after their removal from each
patient. Normal tissues were collected from the region
separated over 2 cm from the cancer boundary. The
tissues were stored in liquid nitrogen until DNA and
RNA extractions were performed.
Evaluation of the methylation statuses of VEGF, FLT1,
and KDR
Promoter methylation of VEGF, FLT1, and KDR was
evaluated by pyrosequencing analysis. Briefly, DNA and
RNA from all tested cell lines and tissue samples
(Table 1) were extracted using the AllPrep DNA/RNA
Mini Kit (Cat. No. 80204; Qiagen, Valencia, CA, USA)
following the manufacturer’s recommended protocol.
DNA and RNA were also extracted from tissue samples
using the AllPrep DNA/RNA Mini Kit, which involved
homogenizing less than 20 mg of each sample in lysis
buffer (Buffer RLT Plus, Cat. No. 1053393; Qiagen,
Valencia, CA. USA) using the TissueLyser II (Qiagen,
Valencia, CA, USA). Subsequently, lysates from each
tissue sample were used for DNA and RNA extraction
after a 3-min centrifugation step at maximum speed.
Pyrosequencing of the VEGF, FLT1, and KDR genes was
performed after bisulfite treatment of 1 μg of genomic
DNA (Zymo EZ DNA Methylation Kit; Zymo Research,
Irvine, CA, USA). PCR for pyrosequencing was per-
formed in a total volume of 50 μL containing 1× buffer
(67 mM Tris-HCl (pH 8.8), 6.6 mM MgCl2, 16.6
NH4SO4, and 10 mM 2-mercaptoethanol), 0.2 mM
dNTP, 1 unit of Taq polymerase, 2 μL (100 ng) of
bisulfite-treated DNA, and 0.1 mM of each forward and
reverse primer, 1 of each primer pair being biotinylated
(B): (VEGF: VEGF-pyro-F, (B)-5'-TAGGGAAGTTGGGT-
GAATGGA-3' and VEGF-pyro-R, 5′-TCCTAAAATAA
CCCCTAACCTTCT-3′; FLT1: FLT1-pyro-F, 5′-ATGGG
TAGGAGGAGGGGTAA-3′ and FLT1-pyro-R, (B)-5'-
TCCCCACCTACCCTCTTCTT-3', and KDR: KDR-pyro-F,
5′-GAGGGTGTAGGTAGGAGAGGATATTTAG-3′ and
KDR-pyro-R, (B)-5′-CCCCCAAAAAACCATCAATATA
TAATC-3′). After a hot start, the PCR cycling conditions
for each tested gene were as follows: 45 cycles of 95 °C for
30 s, annealing at varying temperatures (62 °C for VEGF,
63 °C for FLT1, and 64 °C for KDR) for 30 s, and 72 °C for
30 s. Pyrosequencing and methylation quantification of
the biotinylated PCR product were performed using a
sequencing primer for each gene (VEGF: VEGF-pyro-s,
5′-CCCCTAACCTTCTCCC-3′; FLT1: Flt1-pyro-s, 5′-G
GATAAAGATTTTGAATT-3′; KDR: KDR-pyro-s, 5′-G
GAGAGGATATTTAGGTTG-3′) and Pyro Gold CDT
Reagents (Qiagen), using a PSQ HS 96 Pyrosequencing
System (Qiagen) [5]. Primers for the pyrosequencing were
designed based on the promoter sequences of VEGF
(GenBank Accession Number M63971), FLT1 (Accession
Number D64016), and KDR (Accession Number X89776),
shown in Fig. 1a [4]. We used mean values from all pyro-
sequenced CpG sites (3 adjacent CpG sites for VEGF, 10
for FLT1, and 4 for KDR) to determine the methylation
levels for each gene (Fig. 1b) [4].
Evaluation of VEGF, FLT1, and KDR expression
The expression levels of VEGF, FLT1, and KDR were
evaluated using real-time RT-PCR [4]. Briefly, 2 μg of
total RNA was transcribed using the High Capacity
cDNA RT Kit (Applied Biosystems, Foster City, CA,
USA). Real-time RT-PCR was performed in a Step-One
Real-Time PCR System (Applied Biosystems) using a
20× TaqMan® Gene Expression Assay (Applied Biosystems)
for VEGF (Hs00900054_m1), FLT1 (Hs01052936_m1),
KDR (Hs00176676_m1), or β-actin (Hs99999903_m1) as
an endogenous control. The reaction mixtures for real-
time RT-PCR contained 10 μL of TaqMan Universal Mas-
ter Mix (Applied Biosystems), 1 μL of 20× primer probe
mix, 7-μL distilled water, and 2-μL cDNA. Amplification
was performed by denaturation for 10 min at 95 °C,
followed by 40 cycles of 95 °C for 30 s, 60 °C for 30 s, and
72 °C for 30 s. Reactions were performed in triplicate for
each gene. The expression difference of each target gene
was evaluated using the ΔCT method, normalizing CT
values a target genes to that of β-actin.
Analysis of clear cell RCC data from TCGA
To evaluate relationships between the expression and
methylation of VEGF, FLT1, and KDR using TCGA
data, we used the cBioPortal for Cancer Genomics
(www.cbioportal.org) online tools [18, 19]. First, Kid-
ney Renal Clear Cell Carcinoma (TCGA, Provisional)
data were selected among the listed cancer studies of
the cBioPortal site. Then, we queried mutation fre-
quencies and relationships between DNA methylation
and gene expression of VEGFA, FLT1, and KDR in 320
samples selected from the Kidney Renal Clear Cell
Carcinoma dataset.
Proliferation assays after treatment with anti-VEGF/VEGFR
drugs
The effects of an anti-VEGF antibody (bevacizumab,
expressed in HEK293E cells and purified on a protein A-
Sepharose column), an anti-KDR antibody (Cat. No.
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MAB3572, R&D Systems; Minneapolis, MS, USA), an
anti-FLT1 peptide (Gly-Asn-Gln-Trp-Phe-Ile; synthe-
sized by Peptron, Inc., Daejeon, South Korea) [8], and 2
VEGF-TKIs (sunitinib (Cat. No. PZ0012, Sigma-Aldrich,
St. Louis, MO, USA) and axitinib (Cat. No. PZ0193,
Sigma-Aldrich)) on cell proliferation were examined in
vitro. HUVECs, SNU1 cells, H460 cells, and RCC lines
were treated for 72 h with bevacizumab (2 μg/mL) an
anti-FLT1 peptide (100 μM), an anti-KDR antibody
(4 μg/mL), sunitinib (2 μM), or axitinib (2 μM). Un-
treated cells were used as controls. Proliferation was
then examined using CCK8 assays (Dojindo Molecular
Technologies, Inc., Rockville, MD, USA) following the
manufacturer’s instructions. Briefly, 1 × 104 cells were
seeded in individual wells of 96-well plates (two wells
per cell line) and incubated in growth media at 37 °C
and 5 % CO2. After 24 h, the appropriate drug was
added to one of the two wells, and the cells were grown
for an additional 72 h. The optical density (OD) of each
well was then measured to evaluate cell proliferation in
each well. The proliferation assays were performed in
three independent experiments. The average ODs of
control or treated cells from three replicate assays were
used to determine changes in proliferation after the 72-
h treatment with anti-VEGF/VEGFR drugs. Changes in
proliferation were determined using the ratio (%) of the
average OD observed with treated cells to that observed
with untreated cells.
Evaluation of VEGF, FLT1, and KDR expression after
demethylation
For demethylation experiments, four RCC lines (SNU482,
having low methylation of both FLT1 and KDR; SN12C,
having high FLT1/low KDR methylation; ACHN, having
low FLT1/high KDR methylation; and SNU333, having
high methylation of both FLT1 and KDR) and two control
cell lines (SNU1 and H460) were used. The cell lines were
treated with or without 5 μM DAC (Sigma) each day for
7 days [20]. Changes in the methylation of VEGF, FLT1,
and KDR were compared between untreated and DAC-
treated cells by pyrosequencing. Comparison of each tar-
get gene expression was first normalized to endogenous
gene expression (ΔCT = CT(target gene)–CT(β-actin)) and then
to the reference sample (ΔΔCT =ΔCT(DAC) –ΔCT(No-DAC))
in each tested cell line. Finally, the RQ of each gene was
determined for each tested cell line using the formula,
RQ = 2−ΔΔCT.
Proliferation assay after demethylation and sunitinib
treatment
To evaluate potential synergistic effects of sunitinib
treatment after demethylation, control cells (SNU1 and
H460) or RCC lines were treated with 5 μM DAC, 2 μM
sunitinib, 2 μM axitinib, or a combination of DAC and
sunitinib or axitinib. For the proliferation assays, 1 × 104
cells were seeded in each of two wells of 96-well plates
and incubated in growth medium at 37 °C and 5 % CO2.
After 24 h, DAC, sunitinib, or axitinib was added to one
well. For the combined treatment, DAC was added on
the first day, and sunitinib or axitinib was added after
24 h. Cells were then incubated under these conditions
for an additional 72 h. The OD of each well was mea-
sured to evaluate the proliferation status of the cells in
each well. Proliferation assays were replicated three
times for the control and treated cells. Changes in prolif-
eration were determined using the ratio (%) of the aver-
age OD observed with treated cells to that observed
with untreated cells at 72 h.
Effects of FLT1 or KDR knockdown on proliferation
SNU482 cells, having low methylation of both FLT1
and KDR (Table 1), were used for in vitro knockdown
assays following lentiviral vector-mediated transduction
of shRNAs for FLT1 (FLT1 MISSION shRNA Lentiviral
Transduction Particles; TRCN0000194670; Sigma-
Aldrich) or KDR (KDR MISSION shRNA Lentiviral
Transduction Particles; TRCN0000199129; Sigma-
Aldrich). On day 1, 1.6 × 104 SNU482 cells were seeded
in RPMI medium in separate wells of a 96-well plate.
On day 2, the medium of each well was removed and
replaced with 110 μL of medium containing 8 μg/mL
hexadimethrine bromide. The plate was swirled gently
to mix the well contents, and 2 μL of 106 transducing
units of lentiviral particles for each gene was added to
the appropriate wells. The plate was then incubated for
20 h at 37 °C in a humidified incubator in an atmos-
phere of 5–7 % CO2. On day 3, the medium containing
lentiviral particles was removed from the wells and re-
placed with 120 μL of fresh medium. On day 4, the
medium was removed and replaced with fresh medium
containing 2 μg/mL puromycin. The medium was re-
placed every 3–4 days thereafter. Proliferation inhib-
ition assays were performed after treatment with
bevacizumab, an anti-KDR-antibody, an anti-FLT1-
peptide, sunitinib, and axitinib, as described above.
Analysis of the effects of methylation statuses of VEGF,
FLT1, and KDR on sunitinib sensitivity in patients with
renal cancer
We reviewed data sets from 21 patients who were
treated with sunitinib for metastatic renal cancer be-
tween September 2007 and December 2009 [21]. The
inclusion criteria were as follows: histologically con-
firmed clear cell RCC, measurable lesions by computed
tomography or magnetic resonance imaging, and a per-
formance status of 0–2 as assessed by the Eastern
Cooperative Oncology Group criteria [22] and the number
of risk factors as defined by the Memorial Sloan-Kettering
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Cancer Center Risk Group [23]. Patients with brain me-
tastases were excluded. The objective clinical response
(complete response, partial response, stable disease, or
progressive disease) was assessed using the RECIST cri-
teria [6]. For analysis of the methylation status of VEGF,
FLT1, and KDR, tumor tissues from 13 patients were stud-
ied. The study protocol (File No.: 2014-04-030) was ap-
proved by the Institutional Review Board of Chungnam
National University Hospital. The requirement for in-
formed consent from the patients was waived because of
the retrospective nature of this study.
To evaluate the methylation status in renal cancer tis-
sues, DNA was extracted from paraffin-embedded can-
cer tissues from each patient using the EpiTect Plus
FFPE Lysis Kit (Qiagen). After bisulfite treatment of the
DNA (EpiTect Plus DNA Bisulfite Kit; Qiagen), the
promoter methylation status of VEGF, FLT1, and KDR
for each patient was evaluated by pyrosequencing. The
methylation statuses of these three genes were com-
pared between responders (complete response or partial
response) and nonresponders (stable disease or pro-
gressive disease).
Statistical analysis
Differences in gene expression (ΔCT) according to
changes in promoter methylation were analyzed using
correlation analysis. Changes in gene expression (RQ)
after the in vitro knockdown of FLT1 or KDR were
compared using paired t tests. A GLMM was used to
analyze whether FLT1 or KDR methylation status was
associated with inhibited proliferation following treat-
ment with anti-VEGF/VEGFR drugs in all tested RCC
lines with different FLT1 or KDR methylation statuses.
For the GLMM, we assumed that each RCC line was
randomly selected from each RCC line group classified
according to FLT1 or KDR promoter methylation sta-
tus. Three-factor analysis was performed to evaluate
whether the demethylation of FLT1 or KDR synergistic-
ally enhanced the effects of sunitinib or axitinib treat-
ment in four RCC lines with different FLT1 and/or
KDR methylation statuses. Two-factor analyses relating
the knockdown status of FLT1 or KDR and the inhibitory
effects of the five tested drugs were performed to evaluate
potential statistical interactions. Differences in methyla-
tion in VEGF, FLT1, and KDR between normal and cancer
tissues collected from renal cancer patients were com-
pared using Wilcoxon’s singed-rank test. The relationship
between gene expression and methylation changes in the
renal cancer tissues was also analyzed using correlation
analysis between the reciprocal of the percent methylation
and the RQ values observed in cancer tissues. To compare
differences in FLT1 and KDR promoter methylation levels
between responders and nonresponders in different
groups of renal cancer patients, we used a paired t test.
All statistical analyses were performed using SPSS soft-
ware, version 20.0 (IBM, Chicago, IL, USA) and SAS soft-
ware, version 9.3 (SAS, Cary, NC, USA).
Additional files
Additional file 1: Table S1. Baseline characteristics of 13 advanced RCC
patients treated with sunitinib. (DOCX 14.9 kb)
Additional file 2: Table S2. Characteristics of five advanced RCC
patients who responded to sunitinib treatment. (DOCX 14.2 kb)
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